Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Edwards Lifesciences Yönetim

Yönetim kriter kontrolleri 2/4

Edwards Lifesciences' CEO'su Bernard Zovighian, May2023 tarihinde atandı, in görev süresi 1.42 yıldır. in toplam yıllık tazminatı $ 12.87M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.6% maaş ve 92.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.012% ine doğrudan sahiptir ve bu hisseler R$ 25.43M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 4.4 yıldır.

Anahtar bilgiler

Bernard Zovighian

İcra Kurulu Başkanı

US$12.9m

Toplam tazminat

CEO maaş yüzdesi	7.6%
CEO görev süresi	1.4yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	5.1yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bernard Zovighian'un ücretlendirmesi Edwards Lifesciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$13m	US$973k	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$1b
Dec 31 2022	US$3m	US$642k	US$2b

Tazminat ve Piyasa: Bernard 'nin toplam tazminatı ($USD 12.87M ), BR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.68M ).

Tazminat ve Kazançlar: Bernard 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Bernard Zovighian (56 yo)

1.4yrs

Görev süresi

US$12,869,020

Tazminat

Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bernard Zovighian	CEO & Director	1.4yrs	US$12.87m	0.012% R$ 28.6m
Scott Ullem	Corporate VP & CFO	10.8yrs	US$5.95m	0.045% R$ 109.5m
Donald Bobo	Corporate Vice President of Strategy & Corporate Development	8.7yrs	US$4.29m	0.034% R$ 82.6m
Larry Wood	Corporate VP and Group President of TAVR & Surgical Structural Heart	1.8yrs	US$5.40m	0.034% R$ 81.6m
Andrew Dahl	Principal Accounting Officer	less than a year	Veri yok	0.00029% R$ 699.7k
Todd Brinton	Corporate VP of Advanced Technology & Chief Scientific Officer	5.7yrs	Veri yok	Veri yok
Mark Wilterding	Vice President of Investor Relations	no data	Veri yok	Veri yok
Arnold Pinkston	Corporate VP & General Counsel	5.1yrs	Veri yok	Veri yok
Dirksen Lehman	Corporate Vice President of Public Affairs	11.3yrs	Veri yok	Veri yok
Christine McCauley	Corporate Vice President of Human Resources	12.2yrs	Veri yok	Veri yok
Gary Sorsher	Senior Vice President of Quality & Regulatory Compliance	1.3yrs	Veri yok	Veri yok
Wayne Markowitz	GM & Senior VP of Surgical Structural Heart	1.2yrs	Veri yok	0.00021% R$ 506.7k

5.1yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: E1WL34 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bernard Zovighian	CEO & Director	1.4yrs	US$12.87m	0.012% R$ 28.6m
Kieran Gallahue	Independent Director	9.7yrs	US$335.06k	0.012% R$ 28.8m
Paul LaViolette	Independent Director	4.3yrs	US$329.97k	0.0013% R$ 3.1m
Steven Loranger	Independent Director	8.6yrs	US$335.06k	0.012% R$ 28.6m
Leslie Heisz	Independent Director	8.3yrs	US$356.42k	0.0045% R$ 10.8m
Nicholas Valeriani	Independent Chairman	9.9yrs	US$347.97k	0.011% R$ 27.6m
Leslie Davis	Independent Director	less than a year	Veri yok	Veri yok
David Feinberg	Director	less than a year	Veri yok	Veri yok
Ramona Sequeira	Independent Director	4.4yrs	US$334.97k	0.0018% R$ 4.4m

4.4yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: E1WL34 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Edwards Lifesciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Recent updates

Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024

Robbins Geller Rudman & Dowd LLP Updates on Class Action Lawsuit Against Edwards Lifesciences Corporation

Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million.

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024

Edwards Lifesciences Announces the Release of Data from the Hudle Study

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark

Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023

Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Announces Results of the EU-HYPROTECT Registry

Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

Edwards Lifesciences Corporation to Report Q4, 2022 Results on Jan 31, 2023

Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2023

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

Edwards Lifesciences Corporation to Report Q3, 2022 Results on Oct 27, 2022

Edwards Lifesciences Corporation Announces Results from CLASP IID

Edwards Lifesciences Corporation's Transcatheter Edge-To-Edge Repair Receives FDA Approval

Edwards Lifesciences Corporation Launches SAPIEN 3 Ultra Resilia Valve Following FDA Approval

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022

Edwards Lifesciences Corporation to Report Q2, 2022 Results on Jul 28, 2022

Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2022

Edwards Lifesciences Corporation to Report Q1, 2022 Results on Apr 26, 2022

Edwards Lifesciences Corporation's MITRIS RESILIA Valve Receives FDA Approval for Mitral Replacement Surgeries

Edwards Lifesciences Provides Earnings Guidance for the First Quarter and Full Year of 2022

Edwards Lifesciences Corporation Receives FDA Approval for SAPIEN 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement

Edwards Lifesciences Corporation Provides Sales Guidance for Fiscal 2022

Edwards Lifesciences Announces Clinical and Economic Results from 3M Transcatheter Aortic Valve Replacement Economic Study and the Partner 3 Bicuspid Registry for SAPIEN 3 TAVR Study

Edwards Lifesciences Receives U.S. Food and Drug Administration Clearance for Hypotension Prediction Index Software for Noninvasive Acumen IQ Cuff

Edwards Lifesciences Corporation Presents Clinical Results from Transcatheter Mitral and Tricuspid Programs as Part of the Late-Breaking Clinical Trials at EuroPCR 2021

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2021

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

Edwards Lifesciences Corporation to Report Q4, 2020 Results on Jan 27, 2021

Edwards SAPIEN 3 TAVI Receives Expanded Approval in Canada

Edwards Lifesciences Corporation to Report Q3, 2020 Results on Oct 21, 2020

Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.

Edwards Lifesciences Corporation to Report Q2, 2020 Results on Jul 23, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş